Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (June 2026)
44 slides from Context Therapeutics's investor presentation, Jun 15, 2026
Slide 1: Advancing T Cell Engagers for Solid Tumors
June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, pros
Slide 3: Building a Leading T cell Engager (TCE) Pipeline
Building a Leading T cell Engager (TCE) Pipeline Executive Summary Strategy Developing potentially best-in-class TCE for solid tumors • Tumor antigens that are clinically validated by antibody drug conjugates (ADC) or chimeric antigen receptor T cell therapy (CAR-T) • Limited or weak competition add
Slide 4: Pipeline Overview
Executive Summary Pipeline Overview 4 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) PRECLINICAL PHASE 1 PHASE 2 ANTICIPATED MILESTONES CTIM-76 Claudin 6 (CLDN6) > 50,000 patients Q4 2026: QW updated data Q2 2027: Q3W dosing data CT-95 Mesothelin (MSLN) > 100,000 patients Sept 2026: Preliminary Ph 1a
Slide 5: Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers
Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Executive Summary Context Therapeutics Inc. - June 20265 Synergistic Combination ApproachesOptimized Novel Monotherapies CTIM-76
Slide 6: T Cell Engager Strategy
T Cell Engager Strategy Context Therapeut ics Inc . - June 20266
Slide 7: T Cell Engaging (TCE) Bispecific Antibodies
T Cell Engaging (TCE) Bispecific Antibodies T Cell Engager Strategy Context Therapeutics Inc. - June 20267 Mechanism of Action T-cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T lymphocytes toward malignant cells. These molecules simultaneously bind to a tumor-associat
Slide 8: FDA Approvals for TCE for Solid and Liquid Tumors
10 FDA Approvals for TCE for Solid and Liquid Tumors Recently approved TCE have had strong initial commercial launches T Cell Engager Strategy Context Therapeutics Inc. - June 20268 2024202320222014 2025 Product Target 2025 Revenue1 Blincyto CD19 x CD3 $1,559 million Tecvayli BCMA x CD3 $670 million
Slide 9: TCE Success in Solid Tumors
TCE Success in Solid Tumors Asset Tarlatamab (AMG757) HPN328 QLS31905 IBI389 VIR-5500 JANX007 JNJ-78278343 Xaluritamig (AMG509) Ubamatamab (REGN4018) Target x Effector DLL3 x CD3 DLL3 x CD3 CLDN18.2 x CD3 CLDN18.2 x CD3 PSMA x CD3 PSMA x CD3 KLK2 x CD3 STEAP1 x CD3 MUC16 x CD3 Cancer Indication Smal
Slide 10: CTIM-76 CLDN6 x CD3 bispecific antibody
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - June 202610
Slide 11: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CTIM-76 Program 11 Context Therapeutics Inc. - June 2026 Initial indications of interest based on: • CLDN6 prevalence • Patient population size •
Slide 12: CLDN6 is an Attractive Target for Immunotherapy
CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein. Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Expression increases with cancer disease stage • Tetraspan protein; does not readily intern
Slide 13: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functional
Slide 14: Positive Phase 1a Clinical Data Observed for CTIM-76
Positive Phase 1a Clinical Data Observed for CTIM-76 CTIM-76 has been granted FDA Fast Track Designation CTIM-76 Program Context Therapeutics Inc. - June 202614 Pan-PROC Target Clinical Activity in Late Line PROC 7 (5-16) prior lines of therapy Low Rate of CRS in PROC ~75% of platinum resistant ovar
Slide 15: Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC
Significant Market Opportunity in High Unmet Need CLDN6+ Post-ADC PROC • ~75% of PROC patients are CLDN6+ • No approved treatment option specifically for this biomarker selected PROC population • ~42,000 CLDN6+ PROC patients globally (US, EU7, JP) • CLDN6 has significant target overlap with promisin
Slide 16: CTIM-76 Phase 1a Dose Escalation Trial
CTIM-76 Phase 1a Dose Escalation Trial Target population • Ovarian, endometrial and testicular cancer relapsed to standard of care (all comers) • CLDN6+ positive via IHC (≥10% 1+ staining) Trial objectives • Assess safety and tolerability • Pharmacokinetic and pharmacodynamic data • Evaluate prelimi
Slide 17: CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties
CTIM-76 Exhibits Compelling Pharmacokinetic (PK) Properties CTIM-76 Program Context Therapeutics Inc. - June 202617 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515713. Data as of May 29, 2026. 1 Pasritamig: Autio ESMO 2025 . Q3W = every three weeks. 210 and 280µg doses displayed optimal PK prope
Slide 18: Patient Demographics at Target Doses of CTIM-76
Patient Demographics at Target Doses of 140 to 280 µg CTIM-76 evaluated in heavily pre-treated patients with high tumor burden CTIM-76 Program Context Therapeutics Inc. - June 202618 Baseline Characteristics All Comers N 13 Age, n (range) 61 (29-72) ECOG, n (range) 1 (0-1) Ovarian, n (%) 9 (69) Test
Slide 19: Safety Analysis at Target Doses
Safety Analysis at Target Doses of 140 to 280 µg Observed to be well-tolerated with a favorable safety profile • Adverse events (AE) generally occurred during the first or second dose • Most events were low grade, of short duration, and were reversible with standard management • Low rate of cytokine
Slide 20: CRS in PROC Patients at Target Dose Levels
CRS in PROC Patients at Target Dose Levels Benchmarking CRS profiles across approved and experimental TCE 0% 10% 20% 30% 40% 50% 60% Talvey (GPCR5) Elfrexio (BCMA) Epkinly (CD20) Brenetafusp (PRAME) Imdelltra (DLL3) HPN328 (DLL3) CTIM76 (CLDN6) Pasritamig (KLK2) C RS R at e Grade 1 Grade 2 Grade 3 C
Slide 21: CTIM-76 Interim Phase 1a Data at Target Doses
CTIM-76 Interim Phase 1a Data at Target Doses Tumor reduction combined with manageable CRS profile supports continued clinical development CTIM-76 Program Context Therapeutics Inc. - June 202621 Best Overall % Change in Tumor Size From Baseline* CRS Grade Ef fic ac y Sa fe ty -6% -15% -37% -46% -85%
Slide 22: CTIM-76 Anti-tumor Activity at Target Dose Levels
CTIM-76 Anti-tumor Activity at Target Dose Levels Emerging durability signal, despite weekly dosing during escalation phase CTIM-76 Program 22 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515713. RECIST-evaluable population (n =10 patients at target doses) is defined as having measurable disease
Slide 23: CTIM-76 Anti-tumor Activity at Target Dose Levels: Swimmer Plot
CTIM-76 Program Context Therapeutics Inc. - June 202623 CTIM-76 Anti-tumor Activity at Target Dose Levels Emerging durability signal with the potential to further improve with less frequent CTIM-76 dosing CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515713. Swimmer plot includes all comers at tar
Slide 24: Significant RECIST Response in Ovarian Patient with Liver Lesions
Significant RECIST Response in Ovarian Patient with Liver Lesions CTIM-76 Program Context Therapeutics Inc. - June 202624 Baseline CA125 3108 ng/mL Week 9 CA125 272 ng/mL Week 16 CA125 166 ng/mL • PROC patient administered 140µg • 53-year-old female • High disease burden; liver and peritoneum • 5 pr
Slide 25: T Cell Exhaustion is a Critical Determinant of Tumor Response Durability
T Cell Exhaustion is a Critical Determinant of Tumor Response Durability Q3W dosing may delay T cell exhaustion, improve treatment durability, and be more convenient for patients1 CTIM-76 Program Context Therapeutics Inc. - June 202625 Context Internal Data. CTIM-76-101. Study Patient correlative da
Slide 26: Competitive Profile for CTIM-76 in PROC
CTIM-76 Program Context Therapeutics Inc. - June 202626 Competitive Profile for CTIM-76 in PROC Encouraging tumor response and safety profile in heavily pretreated / ADC-experienced patient population CTIM-76 Multiple Nab-Paclitaxel Azenosertib Brenetafusp Target CLDN6 CDH6, FRα, NaPi2b Microtubule
Slide 27: CT-95 MSLN x CD3 bispecific antibody
CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - June 202627
Slide 28: MSLN Therapies Have the Potential to Reach a Large Patient Population
MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-95 Program 28 Context Therapeutics Inc. - June 2026 Selected Cancer indications Incidence (US Only) R/R Incidence MSLN Positive MSLN Med/High P
Slide 29: MSLN Target Biology
MSLN Target Biology Shed mesothelin (sMSLN) in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - June 202629 MSLN is bound to tumor cells via a GPI-anchor Like many GPI-anchored proteins, MSLN can be cut into smaller fragments1,2 The MSLN gene
Slide 30: CT-95: MSLN x CD3 T cell Engaging Bispecific Antibody
CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN epitope • Affinity tuned MSLN binding • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crossl
Slide 31: Cytotoxicity in the Presence of Soluble MSLN
Cytotoxicity in the Presence of Soluble MSLN CT-95 Intended to Overcome MSLN Sink HPN-536 (Harpoon Therapeutics) binds to soluble MSLN (sMSLN) in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - June 202631 CT-95 +10nM sMSLN +30nM sMSLN HPN-536 +10n
Slide 32: CT-95 Phase 1a/b Study
CT-95 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06756035) CT-95 Program 32 Context Therapeutics Inc. - June 2026 Trial status information provided as of March 20, 2026 0.3 µg/kg 0.18 0.6 µg/kg 0.27 0.9 µg/kg 0.36 1.2 µg/kg Cohort 1 Coho
Slide 33: CT-95 Competitive Landscape
CT-95 Competitive Landscape CT-95 is avidity enhanced, affinity tuned, and binds to membrane-bound MSLN CT-95 Program Context Therapeutics Inc. - June 202633 CT-95 AMG-305 HPN-536 JNJ-79032421 ZW171 Company Context Amgen4 Harpoon1 JNJ Zymeworks2,3 Format 2 + 2 1 + 1 + 2 CDH3 + MSLN dBiTE TriTAC 1+1
Slide 34: CT-202 Nectin-4 x CD3 bispecific antibody
CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - June 202634
Slide 35: Nectin-4 Therapies Have the Potential to Reach a Large Patient Population
Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-202 Program 35 Context Therapeutics Inc. - June 2026 Selected Cancer indications Incidence (US Only) R/R Incidence Nectin-4 Positive Nectin
Slide 36: CT-202: Nectin-4 x CD3 T cell Engaging Bispecific Antibody
CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - June 202636 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal kera
Slide 37: Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin
Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin CT-202 Program 37 Logic Gating Through pH Dependency + Increased Target Selectivity Through Avidity 1 Chang, PNAS, 2021 CD3 Potent T cell activationNo T cell activation High on-/off-rate when bound to Nectin-4 monomer Avidity-enhanced Ne
Slide 38: CT-202 is Highly Active and Well Tolerated Across In Vivo Models
CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - June 202638 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to enfortumab TCE control antibodies in mice Reduced Cytokine Release CT-2
Slide 39: CT-202 Competitive Landscape
CT-202 Competitive Landscape Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator Context Therapeutics Inc. - June 202639 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Asset CT-202 BT74801,2 RNDO-5643 Format 2 + 2 (pH depe
Slide 40: Corporate
Corporate 40 Context Therapeut ics Inc . - June 2026
Slide 41: Anticipated Key Milestones in 2026-2027
Anticipated Key Milestones in 2026-2027 • Multiple data inflection points over the next 12 months • Current cash runway into mid-2027 Corporate PROGRAM target 1H 2026 2H 2026 1H 2027 2H 2027 CTIM-76 Claudin 6 (CLDN6) CT-95 Mesothelin (MSLN) CT-202 Nectin-4 Ph 1a Dose Escalation Ph 1a Q3W Dose Evalua
Slide 42: Experienced Leadership Team
Corporate Experienced Leadership Team Experienced management team Clinical team has developed T cell therapies Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Medical
Slide 43: Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors © Context Therapeutics 2026
Slide 44: Glossary
Glossary ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome DLT Dose limiting toxicity Fab Fragment antigen-binding region FIH First-in-human FPI First Patient In (dosed) FRα Folate r
Context Therapeutics — Investor Presentation (June 2026) on 6ix